Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.45
-0.1150-1.75%
Volume:861.62K
Turnover:5.56M
Market Cap:520.61M
PE:-3.19
High:6.54
Open:6.52
Low:6.36
Close:6.56
Loading ...

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
07 Feb

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Feb

Kura Oncology Price Target Maintained With a $28.00/Share by JMP Securities

Dow Jones
·
07 Feb

Wedbush Adjusts Kura Oncology's Price Target to $26 From $34, Maintains Outperform Rating

MT Newswires Live
·
06 Feb

Kura Oncology Inc : Btig Cuts to Neutral From Buy

THOMSON REUTERS
·
06 Feb

Kura Oncology drops 11% to $8.07 after leukemia update, BTIG downgrade

TIPRANKS
·
06 Feb

Scotiabank would buy Kura on weakness despite KOMET-001 uncertainty

TIPRANKS
·
06 Feb

Kura Oncology Inc : Leerink Partners Cuts Target Price to $23 From $27

THOMSON REUTERS
·
06 Feb

Kura Oncology Inc : Wedbush Raises Target Price to $36 From $34

THOMSON REUTERS
·
06 Feb

Kura Oncology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
06 Feb

Strong Buy Recommendation for Kura Oncology Driven by Promising Clinical Advancements and Strategic Collaborations

TIPRANKS
·
06 Feb

Kura Oncology price target raised to $40 from $37 at H.C. Wainwright

TIPRANKS
·
06 Feb

Kura Oncology’s Strategic Path to Approval: Buy Rating Based on Promising Trial Outcomes and FDA Alignment

TIPRANKS
·
06 Feb

Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Steris (STE)

TIPRANKS
·
06 Feb

Kura Oncology’s Promising Progress and Strategic Alignment Drive Buy Rating

TIPRANKS
·
06 Feb

BRIEF-Kura Oncology And Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial

Reuters
·
06 Feb

Kura Oncology Inc: Komet-017-Ic and Nic Phase 3 Trials Expected to Initiate in 2H 2025

THOMSON REUTERS
·
06 Feb

Kura Oncology Inc: Nda Submission for Ziftomenib on Track for 2Q 2025

THOMSON REUTERS
·
06 Feb

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

THOMSON REUTERS
·
06 Feb

Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), ARS Pharmaceuticals (SPRY)

TIPRANKS
·
15 Jan